Len Rozamus - Theseus Pharmaceuticals VP Operations
| THRXDelisted Stock | USD 3.71 0.14 3.92% |
Insider
Len Rozamus is VP Operations of Theseus Pharmaceuticals
| Phone | 857 400 9491 |
| Web | https://theseusrx.com |
Theseus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1789) % which means that it has lost $0.1789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2555) %, meaning that it created substantial loss on money invested by shareholders. Theseus Pharmaceuticals' management efficiency ratios could be used to measure how well Theseus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Theseus Pharmaceuticals currently holds 3.98 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Theseus Pharmaceuticals has a current ratio of 26.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Theseus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Joo MD | Design Therapeutics | 61 | |
| Leah Neufeld | Immuneering Corp | 51 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Shane Williams | Century Therapeutics | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Jonathan Yingling | Arcus Biosciences | 55 | |
| Thomas Catinazzo | Relay Therapeutics | 47 | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Mark Wallet | Century Therapeutics | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Prof MD | Hookipa Pharma | 80 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Michael Diem | Century Therapeutics | 53 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Carolyn Tang | Arcus Biosciences | 41 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Christopher Garcia | Arcus Biosciences | N/A | |
Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 |
Theseus Pharmaceuticals Leadership Team
Elected by the shareholders, the Theseus Pharmaceuticals' board of directors comprises two types of representatives: Theseus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theseus. The board's role is to monitor Theseus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Theseus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theseus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| DPhil DPHIL, CoFounder Chairman | ||
| Timothy Clackson, Pres CEO | ||
| Len Rozamus, VP Operations | ||
| Nachu Narasimhan, VP Safety | ||
| Bradford Dahms, Chief officer | ||
| WeiSheng Huang, CoFounder Chemistry | ||
| Alicja Januszewicz, VP Culture | ||
| Victor Rivera, VP CoFounder | ||
| Benjamin Enerson, VP Affairs | ||
| Kristine CPA, VP Controller | ||
| MA DPHIL, CoFounder Chairman | ||
| David MD, Chief Officer | ||
| William Shakespeare, CoFounder RD |
Theseus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theseus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (20.19 M) | |||
| Shares Outstanding | 44.65 M | |||
| Shares Owned By Insiders | 2.55 % | |||
| Shares Owned By Institutions | 93.28 % | |||
| Number Of Shares Shorted | 401.68 K | |||
| Price To Earning | 737.67 X | |||
| Price To Book | 0.81 X | |||
| EBITDA | (66.44 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |